/ PORTFOLIO San Francisco, CAIPO July 2019 (NASDAQ: MIRM)Mirum was formed in 2018, with support from RiverVest, to advance maralixibat, an ASBT inhibitor previously developed by Lumena Pharmaceuticals, a RiverVest Fund II company. Mirum went public in July 2019, and RiverVest liquidated its position in the...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAMpex Pharmaceuticals developed inhaled levofloxacin (brand name Quinsair), an antibiotic used for long-term lung infection treatment in people with cystic fibrosis. Levofloxacin is a well-known antibiotic that had been approved and prescribed...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} San Diego, CAOtonomy works to bring new treatment options to patients with hearing and balance disorders. Otonomy’s technology enables drugs to reach targets effectively and safely within the protected inner ear. The company is...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Fort Worth, TXIPO June 2014, then acquired by AstraZeneca December 2015.ZS Pharma developed Lokelma, a drug to treat hyperkalemia, a serious condition characterized by elevated potassium levels in the blood associated with cardiovascular, renal...
/ PORTFOLIO /*! elementor - v3.15.0 - 09-08-2023 */ .elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block} Waltham, MASeQure Dx, Inc. is applying state-of-the-art genomics technologies for gene editor target profiling to advance discovery, clinical development, and diagnostic solutions. Their core technologies, GUIDE-seq and ONE-seq, enable identification of all potential off-target...
/ PORTFOLIO San Francisco, CABluejay Therapeutics, founded in 2021, was developing brelovitug, a fully human monoclonal antibody with Breakthrough Therapy and PRIME designations for chronic hepatitis delta virus (HDV). At the time of acquisition by Mirum Pharmaceuticals, brelovitug was being evaluated in the AZURE Phase 3 registrational...